Clinical Trial: A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naive Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction

U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07082452) titled 'A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naive Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction' on June 23.

Brief Summary: Combination of azacitidine (AZA) for 7 days every 28 days with a continuous daily exposure to Venetoclax (VEN), an oral bcl-2 inhibitor, is now approved for the treatment of acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy due to age (>75 years) or comorbidities. VEN+AZA showed significant overall response rate...